RegeneRx announces positive results from RGN-259 non-clinical study for Dry Eye Syndrome

RegeneRx Biopharmaceuticals, Inc. (NYSE Amex:RGN) (the "Company" or "RegeneRx") today announced the results of its first non-clinical dry eye study using RGN-259, RegeneRx's ophthalmic, preservative-free eye drop for the treatment of Dry Eye Syndrome (DES). In the study, animals were treated with RGN-259, a vehicle control and a positive control, doxycycline. Corneal fluorescein staining was used to measure the surface defects after induction of DES using an industry accepted dry eye model. In animals treated with RGN-259, a "dramatic" and statistically significant reduction in corneal staining (p<0.03) was observed compared to those treated with the vehicle control and equivalent to original levels seen prior to induction of DES. The treatment effect using RGN-259 was also more pronounced than that observed with the positive control, an accepted treatment for dry eye and ocular surface inflammation.

"These findings are very compelling because this is a standardized model widely used to advance drugs into human clinical dry eye studies and has been pivotal in determining treatment efficacy in various dry eye development programs," stated David Crockford, RegeneRx's vice president of clinical and regulatory affairs. "The fact that the study animals had a statistically significant reduction in corneal staining compared to control animals (equivalent to pre-treatment levels) is consistent with the healing effects observed in patients with non-healing corneal ulcers and with previous animal studies using RGN-259. Moreover, we believe this study further illustrates the significant commercial potential of our ophthalmic drug candidate."

Dr. Gabriel Sosne, Associate Professor of Ophthalmology at Wayne State University School of Medicine, Department of Ophthalmology and Anatomy/Cell Biology in Detroit, Michigan, added, "This study is the first direct indication that RGN-259 may be effective as a treatment for dry eye syndrome, one of the most vexing and difficult problems routinely seen by all eye care professionals. The clinical implication of these results suggests that the use of RGN-259 to treat dry eye is not only warranted but could have a major impact in the field." Dr. Sosne is a member of RegeneRx's scientific advisory board.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Physician posture impacts patient experience and outcomes